Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Cash & Equivalents (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Cash & Equivalents for 6 consecutive years, with $11.7 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 62.43% to $11.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.7 million through Dec 2025, up 62.43% year-over-year, with the annual reading at $11.7 million for FY2025, 62.43% up from the prior year.
  • Cash & Equivalents hit $11.7 million in Q4 2025 for Bolt Biotherapeutics, down from $38.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $95.5 million in Q1 2021 to a low of $4.3 million in Q1 2024.
  • Historically, Cash & Equivalents has averaged $26.2 million across 5 years, with a median of $14.1 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: plummeted 71.27% in 2024 and later soared 1260.86% in 2025.
  • Year by year, Cash & Equivalents stood at $27.4 million in 2021, then crashed by 66.24% to $9.2 million in 2022, then rose by 16.94% to $10.8 million in 2023, then crashed by 33.35% to $7.2 million in 2024, then surged by 62.43% to $11.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for BOLT at $11.7 million in Q4 2025, $38.8 million in Q3 2025, and $48.5 million in Q2 2025.